By Amina Niasse and Sneha S K
NEW YORK, July 16 (Reuters) – UnitedHealth Group on Thursday delivered the quarterly financial report investors have been looking for, beating Wall Street’s second-quarter profit expectations and raising its 2026 forecast as it improved its medical cost management.
Shares in the company rose nearly 8% in morning trading after the company reported improvements in its health insurance and Optum health services units, reflecting progress in a year-long turnaround effort.
Chief Financial Officer Wayne DeVeydt cited contributions from cost controls in the Medicare health insurance business as well as higher government reimbursement in Medicaid plans for low-income Americans.
“These results are not a reflection of a trend bending or coming under control, but rather our efforts to start pushing down what is already an elevated number,” said DeVeydt.
UnitedHealth CEO Stephen Hemsley, tasked to steer the company back to earnings growth, has refocused the organization and refreshed half of its top leadership, exited some health insurance products, and committed $1.5 billion to invest in artificial intelligence.
Investors had dumped shares of the healthcare company in April of 2025 after it missed financial estimates and withdrew its financial outlook.
RESULTS CLEAR HIGH BAR
UnitedHealth now expects 2026 adjusted profit per share of $19.50 to $20.00 compared with its original forecast of at least $17.75. Analysts expect a profit of $18.47 per share for 2026, according to data compiled by LSEG.
On an adjusted basis, UnitedHealth earned $6.38 per share in the second quarter, compared with an average analyst estimate of $4.90.
J.P.Morgan analyst Lisa Gill said the forecast update cleared the high bar set by investors, who had been looking for a “path” to $20.00.
UnitedHealth’s results lifted shares of other insurers, which were dragged down in Wednesday’s selloff after Elevance’s annual profit hike failed to impress investors. Shares of Humana and CVS Health also gained.
“Things certainly appear to have stabilized after the crack they had last year and now appear to be improving nicely,” said Greg Halter, Director of Research at Carnegie Investment Counsel. The investment advisory firms owns 104,832 UnitedHealth shares according to its latest regulatory filing.
COST CONTROLS
UnitedHealth reported a second-quarter medical cost ratio – the percentage of premiums spent on medical care – of 86.70%, better than analysts’ average estimate of 88.47% and the year earlier’s 89.4%.
The company said its insurance plan design changes and new pricing on products led to an improvement in the medical cost ratio.
UnitedHealth operates insurer UnitedHealthcare, health services unit Optum and a pharmacy benefit manager, Optum Rx.
The health insurance unit, UnitedHealthcare, reported second-quarter revenue of $86 billion, compared with $86.1 billion in the same quarter last year, while overall revenue rose to $112 billion from $111.6 billion. That beat analyst expectations of about $111 billion, according to LSEG.
Higher costs for insurance, however, drove a membership decline, particularly for people purchasing plans through the Obamacare marketplace, where extra pandemic-era government subsidies expired, said DeVeydt.
Recovering growth margins in the company’s commercial business, which includes Obamacare plans, will take longer than originally anticipated, said UnitedHealthcare CEO Tim Noel.
OPTUM IMPROVEMENT
Second-quarter operating income for Optum jumped 29% from a year earlier to $4 billion, driven by improved operations at its technology segment and better access to care in its clinical unit.
In the previous quarter, Optum’s earnings had dragged as its operating income fell 15% year-over-year to $3.3 billion.
The AI tools the company has introduced this year have reduced the administrative burden and increased the amount of time Optum Health clinicians can spend treating patients, DeVeydt said.
“We said, with Optum Health, this would be a multi-year journey to return to historical growth levels and margins,” said DeVeydt, who expects revenue growth to fully return in 2028. “I would say we are ahead of schedule in year one.”
(Reporting by Amina Niasse in New York, additional reporting by Sneha S K and Sriparna Roy in Bengaluru; Editing by Caroline Humer, Christopher Cushing, Shinjini and Nick Zieminski)
Comments